LEO Pharma agreed to acquire worldwide rights to drug candidate dersimelagon from Tanabe Pharma for up to $435M in up-front and near-term milestone payments. The deal signals pipeline expansion and could support future revenue optionality if clinical milestones are met, though full economics depend on later development success.
LEO Pharma agreed to acquire worldwide rights to drug candidate dersimelagon from Tanabe Pharma for up to $435M in up-front and near-term milestone payments. The deal signals pipeline expansion and could support future revenue optionality if clinical milestones are met, though full economics depend on later development success.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
